Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Total Revenues of €174.7 million in line with guidance, including €157.9 million in product sales Strong year-end cash position of €109.7 million, with enhanced financial flexibility following...
-
SUMMIT NDA for bezuclastinib in patients with NonAdvSM submitted in December 2025; APEX NDA submission for bezuclastinib in patients with AdvSM on track for 1H 2026PEAK NDA initiated for bezuclastinib...
-
Namodenoson’s Favorable Safety Profile and Broad Patent Portfolio Positions it as a Promising Candidate in the Growing Obesity Treatment Market Ramat Gan, Israel, Feb. 17, 2026 (GLOBE NEWSWIRE) -- ...
-
Distribution agreement
-
15% royalty income increase 11% total revenue increaseTripled net cash position Phase 3 program with fosmanogepix progressing as plannedFinancial guidance FY 2026: Double-digit increase in total...
-
Dublin, Feb. 16, 2026 (GLOBE NEWSWIRE) -- The "Clinical Analytics Market by Offering (Raw Data, Platform), Source (EHR, Trials, Claims, RWE), Use Case (CDSS, RPM, PHM, R&D, Pharmacovigilance,...
-
Ottawa, Feb. 16, 2026 (GLOBE NEWSWIRE) -- The global bioengineering market size surpassed USD 295.28 billion in 2025 and is expected to be worth around USD 1,484.98 billion by 2035, poised to grow...
-
Lyon (France), February 13, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that following a review of the benefits and risks of the Company’s...
-
Based in New Jersey (USA), to lead ORYZON’s CNS clinical development MADRID and CAMBRIDGE, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a...
-
BOSTON and OAK BROOK, Ill. and SACRAMENTO, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- After rigorous deliberation, Eleos, the leader in AI for behavioral health, today announced that the California...